Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
Theocharis Koufakis, Омар Мустафа, Vasilis Tsimihodimos, Ramzi Ajjan, Kalliopi Kotsa
Topics & Concepts
MedicineClinical endpointHeart failurePlaceboInternal medicineClinical trialDiabetes mellitusRenal functionEjection fractionCardiologyAlbuminuriaGlycated hemoglobinRandomized controlled trialType 2 diabetesEndocrinologyPathologyAlternative medicineDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerPotassium and Related Disorders